The emergence of Martin Shkreli as the face of pharma has frustrated many within the industry, particularly the physicians and scientists drawn to this work by the challenge of developing new medicines for difficult diseases.
Mathai Mammen, The Anti-Shkreli, Brings Heart And A Touch Of Vagelos To Merck R&D
unknownx500
More posts by Park Square Executive Search
Recent posts from Park Square Executive Search